Oem By Qiagen

Oem By Qiagen company information, Employees & Contact Information

Explore related pages

Related company profiles:

OEM by QIAGEN puts the components from the vast QIAGEN product range at your disposal, including: • Enzymes and PCR master mixes • Oligos • Buffers and reagents • DNA/RNA purification technologies OEM by QIAGEN can assist you: If you’re working on an innovative commercial assay and want to make sure you get to market first. If you wish to integrate proven technologies into your workflows. At OEM by QIAGEN, we can help with customized solutions and bulk manufacturing flexibility that may surprise you. We offer: • Prototype development • Sampling and testing • Kitting • Packaging and labelling • Manufacturing to scale according to GMP guidelines Our manufacturing facilities are ISO 9001 and ISO 13485 certified. We will work with you to assure REACH compliance and supply security. Allow OEM by QIAGEN to be your trusted bulk supplier with fast turnaround and full confidentiality. Our OEM portfolio highlights: • Commercial enzymes in bulk – We can customize formulation, concentration, package volume and manufacturing quantities to match your changing needs. We offer lyophilization capabilities and more. Simplify your PCR assay supply chain. • Custom oligonucleotides – We specialize in high-purity customized oligo manufacturing following GMP guidelines. Our products are used in a variety of research and molecular diagnostic applications. • Nucleic acid purification – With our proven DNA and RNA sample processing chemistries, which are used by labs worldwide, you can quickly achieve commercial excellence. Accelerate your innovation with our OEM spin columns. Gain a competitive advantage in extraction, PCR and next-generation sequencing methods with bulk components from OEM by QIAGEN.

Company Details

Employees
75
Address
Qiagen Straße 1, Hilden,north Rhine-Westphalia 40724,germany
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Hilden, North Rhine-Westphalia
Looking for a particular Oem By Qiagen employee's phone or email?

Oem By Qiagen Questions

News

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG TradingView

Nov 4 Q3 2025 results release — QIAGEN to issue results Nov 4 (22:05 Frankfurt) and host Nov 5 webcast - Stock Titan

Nov 4 Q3 2025 results release — QIAGEN to issue results Nov 4 (22:05 Frankfurt) and host Nov 5 webcast Stock Titan

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast - Business Wire

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast Business Wire

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds - Yahoo Finance

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds Yahoo Finance

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast - The AI Journal

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast The AI Journal

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability - Business Wire

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability Business Wire

PTA-AFR: QIAGEN N.V.: Pre-announcement of a financial report according to articles 114 - 117 WpHG - TradingView

PTA-AFR: QIAGEN N.V.: Pre-announcement of a financial report according to articles 114 - 117 WpHG TradingView

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds - Business Wire

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds Business Wire

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - Yahoo Finance

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership Yahoo Finance

PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView

PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR TradingView

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels - Business Wire

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels Business Wire

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships Business Wire

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board - Business Wire

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board Business Wire

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Business Wire

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) Business Wire

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software - Business Wire

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software Business Wire

QIAGEN delivers solid Q4 2024 growth ahead of outlook - Business Wire

QIAGEN delivers solid Q4 2024 growth ahead of outlook Business Wire

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation - Business Wire

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation Business Wire

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast - Business Wire

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast Business Wire

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG TradingView

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million - Business Wire

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million Business Wire

160 Tests Per Day: QIAGEN's New QIAstat-Dx Rise System Receives FDA Clearance for Rapid Diagnostics - Stock Titan

160 Tests Per Day: QIAGEN's New QIAstat-Dx Rise System Receives FDA Clearance for Rapid Diagnostics Stock Titan

QIAGEN Launches New Custom Solutions for Enhanced Microbial Analysis - Quiver Quantitative

QIAGEN Launches New Custom Solutions for Enhanced Microbial Analysis Quiver Quantitative

QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology - GlobeNewswire

QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology GlobeNewswire

QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results - GlobeNewswire

QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results GlobeNewswire

QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs - GlobeNewswire

QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs GlobeNewswire

QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance - GlobeNewswire

QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance GlobeNewswire

Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement - Yahoo Finance

Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement Yahoo Finance

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery - GlobeNewswire

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery GlobeNewswire

QIAGEN expands QIAstat-Dx syndromic testing menu in the - GlobeNewswire

QIAGEN expands QIAstat-Dx syndromic testing menu in the GlobeNewswire

DNA Labs International solves significant cold cases with QIAGEN workflow - Police1

DNA Labs International solves significant cold cases with QIAGEN workflow Police1

Thermo Fisher Scientific Confirms Offer to Acquire QIAGEN Shares Expires on August 10 - Thermo Fisher Scientific

Thermo Fisher Scientific Confirms Offer to Acquire QIAGEN Shares Expires on August 10 Thermo Fisher Scientific

Thermo Fisher Scientific to Acquire QIAGEN N.V. - Thermo Fisher Scientific

Thermo Fisher Scientific to Acquire QIAGEN N.V. Thermo Fisher Scientific

Top Oem By Qiagen Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant